BMS, says Kaiser, is tripling down on BCMA across different modalities. Multiple avenues for therapy Among these novel modalities, chimeric antigen receptor (CAR) T cells have the longest history ...

Schematic illustration explaining the working principle of BCMA-CD19 bispecific CAR T cells used in current study. CD19 is the pan B cell marker but not expressed in long-lived plasma cells and ...

This CAR helps the T cells recognize and destroy cells expressing BCMA, which is primarily found in malignant multiple myeloma B-lineage cells, late-stage B cells, and plasma cells. The CARVYKTI ...

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

There was also a 2.5-fold increase over DVd on the proportion of patients with minimal residual disease (MRD ... at earlier-line use. Two BCMA-directed CAR-T therapies have been approved ...

Anito-cel is a B-cell maturation antigen chimeric antigen receptor (BCMA CAR) T-cell therapy ... overall survival, minimal residual disease negativity, and safety will be the secondary endpoints.

In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...